DOCSLIB.ORG

Epidural Ketamine for Postoperative Analgesia

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Epidural Ketamine for Postoperative Analgesia 16 Mohamed Naguib M~ SCH MSC, Epidural ketamine Yaw Adu-Gyamfi MB, CHS FVARCS, FWACS, Gamil H. Absood PHO, for postoperative Hesham Farag ras scH FFARCS, Henry K. Gyasi MB CHa FFARCSl analgesia Thirty-four patients of ASA physical status 1 or H Following the identification of opiate receptors in scheduled for gall bladder surgery were studied in a the spinal cord, 1 the epidural and intrathecal use comparative prospective trial to evaluate the efficacy of of opioids has increased. However, these methods epidural and intramuscular ketamine for postoperative of pain relief are not without side-effects, 2 the most pain relief. They were divided randomly into three serious of which is delayed respiratory depression.3 groups. Group I (11 patients) received 30rag intra- Ketamine [2-(O-Chlorophenyl)-2-(methylamino) muscular ketamine. Group 11 (10 patients) and Group 111 cyclohexanone HCI] is a potent analgesic. 4 Recent (13 patients) received 10 and 30rag ketamine in 1Oral studies indicate that analgesia produced by ketamine saline respectively, through epidural catheters. Pain was is mediated by opiate receptors, s'6 Since ketamine evaluated every two hours for the first 24 hours post. administered systemically is unlikely to produce operatively by using a linear analogue pain scale from respiratory depression, 7 it seemed to offer an 0-10. Ketamine was given on the patient's request and obvious advantage over the opiates. whenever the pain score exceeded three. Ketamine pro- The demonstration of the safety of intrathecal duced analgesia in all patients studied. The reduction of ketamine with preservatives in baboons by Brock- pain score after two andJbur hours in Group I and lll was Utne et al. 8 led Makowitz et al. 9 to administer significant when compared to Group H. Seven patients ketamine with preservative into the extradural space (54 per cenO in Group II1 did not require further to humans suffering from chronic pain, in an analgesia after the initial injection. However, following uncontrolled study. 10 mg epidurat ketamine or 30 mg IM ketamine, post. This paper reports a prospective randomized operative pain was more frequent. Four patients who study with two different doses of epidural ketamine received epidural ketamine complained of transient to determine the analgesic and side effects of this burning pain in the back during injection. No patient technique while employing intramuscular (IM) developed respiratory depression, psychic disturbance, ketamine as a control, in patients undergoing cardiovascular instability, bladder dysfunction or neuro- gallbladder surgery. logic deficit. It is concluded that 30 mg epidural ketamine is a safe and effective method for postoperative Methods analgesia. Thirty-four patients of ASA physical status I or II undergoing gallbladder surgery with a subcostal incision were studied. Patients with a previous history of hypertension, hyperthyroidism or psychi- attic disorders were excluded. This study was Key words approved by the institutional review committee and ANALGESICS:ketamine; ANAESTHETICTECHNIQUES: informed consent was obtained. epidural; PAIN" postoperative. Diazepam 10 mg was given orally as premedica- tion to all patients. In the operating room an From the Department of Anesthesiology, King Faisal intravenous (IV) line was established, the electro- University, King Fahd Hospital and the Department cardiograph (ECG) was monitored continuously of Biostatisties, King Faisal University (Dr. Absood). and arterial blood pressure was monitored every Address correspondence to: Dr. M. Naguib, Dept. of five minutes by an electronic oscillotonometer Anaesthesiology, King Fahd Hospital, P.O. Box (Dinamap). 2208, A1-Khobar, 31952, Saudi Arabia. A standard anaesthetic was administered to all CAN ANAESTH SOC J 1986 / 33:1 / ppl6~21 Naguib etal.: EPIDURAL KETAMINE FOR POSTOPERATIVE ANALGESIA 17 patients, This consisted of phenoperidine 2 mg, TABLE I Patientdata thiopentone 5 mg'kg -~ and succinylcholine Group I Group H Group 111 1 mg.kg -I IV. After intubation, anaesthesia was Intramuscular Epidural Epidural maintained with 70 per cent nitrous oxide in ketamine ketamine ketamine oxygen, halothane 0.5 per cent and pancuronium (30 rag) (10 rag) (30 rag) 0.1 mg-kg -l. Ventilation was controlled with a n=11 n=lO n=13 Manley Servovent to maintain normocapnia and Age (yr) end tidal CO2 was monitored by Datex infrared CO2 (mean -+ SD) 38.2-+10.6 37.2+11.2 38.6-+11.4 analyser. Sex (male/female) 4/7 3/7 4/9 Ketamine with benzethonium chloride as the Body Weight (kg) preservative was used. Patients were randomly (mean+-SD) 67.5+_11.8 62.8+-13.9 68.9+-6.0 allocated to one of three groups. Patients in Group I (control group) received 30 mg ketamine intramus- cularly (IM) for postoperative analgesia, whereas looked for and the patient's general condition was patients in Groups II and III received 10 and 30 mg observed during the trial. ketamine in 10 ml saline respectively through epi- Within 48 hours of ketamine injection, and dural catheters for postoperative pain relief. The before discharge from the hospital, all patients were epidural catheters were inserted at the end of the interviewed and a detailed neurological examina- operation using aseptic technique, at the lumbar tion was carded out and the results were recorded. vertebral level of L1-2 and advanced cephalad for 3-5 cm. Nothing was given through the catheters Statistical methods until the patients were fully recovered from the The Mann-Whitney Test was used to compare the general anaesthetic and complained of pain. medians of two independent samples. It was uti- Pain was evaluated initialy in the recovery room lized to test the difference between the groups with and then every two hours for the first 24 hours respect to the reduction in pain score after two and postoperatively by using the linear analogue pain four hours, also to test the difference between the scale from 0-10. The scale was explained to every median times until the second dose of ketamine was patient preoperatively. "Zero" corresponds to "no needed and lastly to compare the medians of the pain" and "ten" corresponds to "severe unbearable number of injections needed in 24 hours. The differ- pain." Ketamine was given on the patient's request ence was considered significant when p < 0.05. and whenever the pain score exceeded three. The Fisher's exact test was performed to test the onset and the degree of pain relief were recorded. homogeneity between groups in terms of the pro- The data were collected by one of the investigators. portion of patients who needed only one dose of Pulse, blood pressure and respiratory rate were ketamine versus those who received more than one recorded before the administration of ketamine. injection during the first 24 hours postoperatively. These observations were repeated at 5, 10, 15 and 30 minutes after ketamine administration. Hyper- tension was considered to be present if the systolic Results blood pressure increased by more than 15 mmHg Patients in each of three groups were comparable in above its previous level. Respiratory depression age, sex and body weight (Table 1). The mean pain was considered to be present if respiratory rate fell score and the total dose of ketamine administered to to eight or less per minute. Arterial blood gases each patient during 24-hour period are shown in were performed before and 30 minutes after keta- Tables II and III respectively. The time intervals mine administration in a few patients in each group (mean -+ S.D.) after the procedure at which the first at the beginning of the trial but were discontinued dose of ketamine was given to the patients were because no changes in blood gases were observed. 34.5 +-- 7.5, 36.5 -+ 11.6 and 36.1 +-- 9.8 minutes in In addition, all patients were observed for nau- Groups I, II and ILl respectively. Ketamine gave sea, vomiting, disturbed micturition, hallucination pain relief in all patients. In the first two hours, after and any other side effects. the administration of ketamine, Group HI had a Changes in sensory and motor functions were significantly greater reduction in pain score than 18 CANADIAN ANAESTHETISTS' SOCIETY JOURNAL TABLE II Meanpain score (-SD) daring first 24 hours (p < 0.01) each as compared to Group 1I. Although following operation the reduction of pain score in Group III was greater Group I Group H Group III than Group I after four hours, this difference was 134 Epidural Epidural not statistically significant (p < 0.1). ketamine ketamine ketamine Regarding the time until a second injection was (30 rag) (10 rag) (30 rag) needed, this was significantly longer in Group III Postoperative Pain score Pain score Pain score when compared with either Group I (p = 0.001) or period n=11 n=10 n=13 Group II (p < 0.001), and it was longer but not Initial pain statistically significant in Group I when compared score 6.1 - 0.9 5.9 --- 0.9 6.1 • 1.0 to Group I1. 2hours 1.8 - 0.3 2.7 +- 1.4 1.3 -+ 0.4 The number of injections needed in 24 hours in 4hours 2.7 • 1.1 3.3 • 2.6 1.8 • 1.4 Group I was greater than in Group HI (p < 0.005) 6hours 2.1 - 0.5 3.1 -+ 2.5 1.7 • 1.2 8hours 1.8 - 0.9 2.6 --- 1.4 1.4 • 1.3 but it was less than that of Group II (p < 0.05). 10hours 1.9 • 0.8 2.4 • 2.2 1.1 --- 1.1 Furthermore, the number of injections was signifi- 12hours 2.0 + 0.9 1.6 • 0.g 0.7 --+ 0.6 cantly less in Group IU than in Group II (p < 0.001). 14hours 1.7 • 0.9 2.0 -+ 1.7 0.5 • 0.8 Fisher's exact test (Table IV) showed that the 16hours 1.2 +- 0.9 1.9 +- 1.0 0.4 • 0.7 proportion of patients who needed only one dose of 18hours 1.0 --- 0.6 2.1 + 1.9 0.3 • 0.8 20hours 0.8 • 0.5 0.6 • 0.4 0.2 • 0.4 ketamine during the first 24 hours postoperatively 22hours 0.9 -+ 0.6 0.9 -+ 0.8 0.2 • 0.4 was much higher and significant in Group HI when 24hours 0.8 • 0.5 0.6 --- 0.4 0.2 • 0.4 compared with either Group I (p = 0.005) or Group II (p = 0.007), but the difference was not significant between Group I and II.
Load more

Recommended publications
  • Recommended Methods for the Identification and Analysis of Fentanyl and Its Analogues in Biological Specimens
    Recommended methods for the Identification and Analysis of Fentanyl and its Analogues in Biological Specimens MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Recommended Methods for the Identification and Analysis of Fentanyl and its Analogues in Biological Specimens MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES UNITED NATIONS Vienna, 2017 Note Operating and experimental conditions are reproduced from the original reference materials, including unpublished methods, validated and used in selected national laboratories as per the list of references. A number of alternative conditions and substitution of named commercial products may provide comparable results in many cases. However, any modification has to be validated before it is integrated into laboratory routines. ST/NAR/53 Original language: English © United Nations, November 2017. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. Mention of names of firms and commercial products does not imply the endorse- ment of the United Nations. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. Acknowledgements The Laboratory and Scientific Section of the UNODC (LSS, headed by Dr. Justice Tettey) wishes to express its appreciation and thanks to Dr. Barry Logan, Center for Forensic Science Research and Education, at the Fredric Rieders Family Founda- tion and NMS Labs, United States; Amanda L.A.
    [Show full text]
  • Removing Samidorphan from Schedule II
    The Acting Administrator of the Drug Enforcement Administration issued an order to extend the temporary schedule I status of ethyl 2-(1-(5- fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate (Other name: 5F-EDMB-PINACA); methyl 2-(1-(5-fluoropentyl)-1H-indole-3- carboxamido)-3,3-dimethylbutanoate (Other name: 5F-MDMB-PICA); N- (adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (Other names: FUB-AKB48, FUB-APINACA, AKB48, N-(4-fluorobenzyl)); 1-(5- fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-indazole- 3-carboxamide (Others names: 5F-CUMYL-PINACA; SGT-25); and (1-(4- fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (Other name: FUB-144), and their optical, positional, and geometric isomers, salts, and salts of isomers. This order will extend the temporary scheduling of 5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL- PINACA and FUB-144 for one year or until the permanent scheduling action for these substances is completed, whichever occurs first. This order was published in the March 31, 2021 issue of the Federal Register, Volume 86, Number 60, pages 16669-16670 and was effective April 16, 2021. The Acting Administrator of the Drug Enforcement Administration issued a final rule removing samidorphan (3-carboxamido-4-hydroxy naltrexone) and its salts from the schedules of the Controlled Substances Act. This final rule was published in the April 19, 2021 issue of the Federal Register, Volume 86, Number 73, pages 20284-20286 and was effective April 19, 2021. This action was based upon the following: 1. Samidorphan does not possess abuse or dependence potential, 2.
    [Show full text]
  • The International Drug Control Conventions
    ST/CND/1/Add.1/Rev.3 The International Drug Control Conventions Schedules of the Single Convention on Narcotic Drugs of 1961 as amended by the 1972 Protocol, as at 22 April 2017 UNITED NATIONS New York, 2017 ST/CND/1/Add.1/Rev.3 © United Nations, 2017. All rights reserved, worldwide. Schedules of the Single Convention on Narcotic Drugs of 1961 as amended by the 1972 Protocol, as at 22 April 2017 List of drugs included in Schedule I Acetorphine 3-O-Acetyltetrahydro-7α-(1-hydroxy-1-methylbutyl)- 6,14-endo-ethenooripavine Acetyl-alpha-methylfentanyl N-[1-(α-Methylphenethyl)-4-piperidyl]acetanilide Acetylfentanyl N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]acetamide Acetylmethadol 3-Acetoxy-6-dimethylamino-4,4-diphenylheptane AH-7921 3,4-dichloro-N-{[1- (dimethylamino)cyclohexyl]methyl}benzamide Alfentanil N-[1-[2-(4-Ethyl-4,5-dihydro-5-oxo-1H-tetrazol-1-yl) ethyl]-4-(methoxymethyl)-4-piperidinyl]-N- phenylpropanamide Allylprodine 3-Allyl-1-methyl-4-phenyl-4-propionoxypiperidine Alphacetylmethadol α-3-Acetoxy-6-dimethylamino-4,4-diphenylheptane Alphameprodine α-3-Ethyl-1-methyl-4-phenyl-4-propionoxypiperidine Alphamethadol α-6-Dimethylamino-4,4-diphenyl-3-heptanol alpha-Methylfentanyl N-[1-(α-Methylphenethyl)-4-piperidyl]propionanilide alpha-Methylthiofentanyl N-[1-[1-Methyl-2-(2-thienyl)ethyl]-4-piperidyl] propionanilide Alphaprodine α-l,3-Dimethyl-4-phenyl-4-propionoxypiperidine Anileridine 1-p-Aminophenethyl-4-phenylpiperidine-4-carboxylic acid ethyl ester Benzethidine 1-(2-Benzyloxyethyl)-4-phenylpiperidine-4-carboxylic acid ethyl ester
    [Show full text]
  • Outline for Controlled Substances Program
    Environmental Health and Safety Controlled Substances Program Date of Issuance: Review Date: 10/1/2019 (no changes) 10/01/2018 Revision Number: Initial Prepared by: EH&S Table of Contents HEADINGS Introduction Applicability Responsibilities Registration Requirements Authorized Use Ordering/Purchasing Administering and Dispensing Inventory Procedures (Continuing Records) Security Disposal FORMS: Registering or renewing a DEA or state license (CMU) Controlled Substances Authorized users list (CMU) Employee questionnaire for those with access to controlled substances (CMU) Record of Form 222 use (Order form) (CMU) Records of Controlled Substance Purchases (CMU) Record of Controlled Substance Administering and dispensing (CMU) Controlled Substance Physical Inventory (CMU) DEA Registration of Persons doing research or analysis (Form 225) DEA Registration of Dispensers (Form 224) DEA Registration Instructional (Form 224 and 226 to renew) DEA Report of loss or theft (Form 106) DEA Report of drugs surrendered (From 41) DEA SCHEDULES: Schedule I Schedule II Schedule III Schedule IV Schedule V INTRODUCTION State and Federal regulations have been promulgated concerning the use and handling of US Department of Justice Drug Enforcement Administration (DEA) controlled substances. These regulations are in place to address materials which are or have the potential to be addictive or habit forming. These substances have been categorized into “schedules” that have been created by the DEA to reflect their level of concern. The “Carnegie Mellon University DEA Controlled Substances Program” is intended to ensure that Carnegie Mellon University is in compliance with our regulatory requirements. Required activities under the DEA include: 1. Registration of your work with the DEA and with Carnegie Mellon’s Department of Environmental Health and Safety (EH&S).
    [Show full text]
  • Supplement 1: Additional Tables and Figures
    BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Global Health Supplement 1: Additional tables and figures Box S1: Substances included and excluded from the International Narcotic Control Board (INCB) data on narcotic consumption, in alphabetical order. Opioids included in the opioid consumption calculation: 1. (+)-cis-3-methylfental 35. Bezitramide 2. 3-Acetylmorphine 36. Butyrfentanyl 3. 3-Methylfentanyl 37. Carfentanil 4. 3-Methylthiofentanyl 38. Carfentanyl 5. 3-Monoacetylmorphine 39. Clonitazene 6. 4-Fluoroisobutyrfentanyl 40. Codeine 7. 6-Acetylmorphine 41. Codeine-6GLUC 8. 6-Monoacetylmorphine 42. Codeine-6-glucuronide 9. Acetorphine 43. Codeine-Methyl 10. Acetyl-alpha-methylfentanyl 44. Codeine-N-oxide 11. Acetyldihydrocodeine 45. Codoxime 12. Acetylfentanyl 46. Conc. of poppy straw (C) ACA 13. Acetylmethadol 47. Conc. of poppy straw (C) AMA 14. Acetylmorphine 48. Conc. of poppy straw (C) AOA 15. Acrylfentanyl 49. Conc. of poppy straw (C) ATA 16. AH-7921 50. Conc. of poppy straw (C) GW 17. Alfentanil 51. Conc. of poppy straw (M) ACA 18. Allylprodine 52. Conc. of poppy straw (M) AMA 19. Alphacetylmethadol 53. Conc. of poppy straw (M) AOA 20. Alphameprodine 54. Conc. of poppy straw (M) ATA 21. Alphamethadol 55. Conc. of poppy straw (M) GW 22. alpha-Methylfentanyl 56. Conc. of poppy straw (N) GW 23. alpha-Methylthiofentanyl 57. Conc. of poppy straw (O) 24. Alphaprodine 58. Conc. of poppy straw (O) ACA 25. Anileridine 59. Conc. of poppy straw (O) AMA 26. Benzethidine 60. Conc. of poppy straw (O) AOA 27.
    [Show full text]
  • Narcotic Drugs Stupefiants Estupefacientes
    E/INCB/1993/21Supp.6 INTERNATIONAL NARCOTICS CONTROL BOARD - VIENNA SUPPLEMENT No. 6 TO NARCOTIC DRUGS ESTIMATED WORLD REQUIREMENTS FOR 1994 STATISTICS FOR 1992 ESTIMATES UPDATED AS OF 30 JUNE 1994 ORGANE INTERNATIONAL DE CONTROLE DES STUPEFIANTS - VIENNE SUPPLEMENT N° 6 A r STUPEFIANTS EVALUATIONS DES BESOINS DU MONDE POUR 1994 STATISTIQUES POUR 1992 EVALUATIONS A JOUR AU 30 JUlN 1994 JUNTA INTERNACIONAL DE FISCALlZACION DE ESTUPEFACIENTES - VIENA SUPLEMENTO N.o 6 A ESTUPEFACIENTES PREVISIONES DE LAS NECESIDADES MUNDIALES PARA 1994 ESTADfsTICAS PARA 1992 PREVISIONES ACTUALlZADAS AL 30 DE JUNIO DE 1994 ~If..~~ ~ ~-tR UNITED NATIONS - NATIONS UNIES - NACIONES UNIDAS 1994 The updating of Table A is carried out by means of 12 monthly supplements. In order to facilitate the task of the exporting countries, the 12 supplements now report all the totals of the estimates and not only the amended data. In this way, each supplement cancels and replaces the published table in its entirety. In order to accelerate the transmission of the supplements to the competent national authorities, the 12 supplements will appear in English. Reading of these 12 supplements in French and Spanish may be facilitated by consulting the indexes of countries and territories and of narcotic drugs appearing in the annual publication. La mise El jour du tableau A s'effectue au moyen de douze supplements mensuels. Afin de faciliter la tache des pays exportateurs, les douze supplements contiennent tous les totaux des evaluations et non pas seulement les chiffres qui ont ete modifies. De celte maniere, chaque supplement annule et remplace entierement le tableau publie.
    [Show full text]
  • G.S. 90-89 Page 1 § 90-89. Schedule I Controlled Substances. This
    § 90-89. Schedule I controlled substances. This schedule includes the controlled substances listed or to be listed by whatever official name, common or usual name, chemical name, or trade name designated. In determining that a substance comes within this schedule, the Commission shall find: a high potential for abuse, no currently accepted medical use in the United States, or a lack of accepted safety for use in treatment under medical supervision. The following controlled substances are included in this schedule: (1) Opiates. – Any of the following opiates or opioids, including the isomers, esters, ethers, salts and salts of isomers, esters, and ethers, unless specifically excepted, or listed in another schedule, whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation: a. Acetyl-alpha-methylfentanyl (N[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacet amide). b. Acetylmethadol. c. Repealed by Session Laws 1987, c. 412, s. 2. d. Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl/-4-piperidinyl]-N-phenylpro panamide). e. Allylprodine. f. Alphacetylmethadol (except levo-alphacetylmethadol, also known as levomethadyl acetate and LAAM). g. Alphameprodine. h. Alphamethadol. i. Alpha-methylfentanyl (N-(1-(alpha-methyl-beta-phenyl) ethyl-4-piperidyl) propionalilide; 1(1-methyl-2-phenyl-ethyl)-4-(N-propanilido) piperidine). j. Benzethidine. k. Betacetylmethadol. l. Beta-hydroxfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N-phenylpropanamide ). m. Beta-hydroxy-3-methylfentanyl (N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-N-phenylpro panamide). n. Betameprodine. o. Betamethadol. p. Betaprodine. q. Clonitazene. r. Dextromoramide. s. Diampromide. t. Diethylthiambutene. u.
    [Show full text]
  • Pdf | 6.4 Mb | Depressants
    3 DEPRESSANTS 3 DEPRESSANTS 2019 2019 © United Nations, June 2019. All rights reserved worldwide. ISBN: 978-92-1-148314-7 eISBN: 978-92-1-004174-4 United Nations publication, Sales No. E.19.XI.9 This publication may be reproduced in whole or in part and in any form for educational or non-profit purposes without special permission from the copyright holder, provided acknowledgement of the source is made. The United Nations Office on Drugs and Crime (UNODC) would appreciate receiving a copy of any publication that uses this publication as a source. Suggested citation:, World Drug Report 2019 (United Nations publication, Sales No. E.19.XI.8). No use of this publication may be made for resale or any other commercial purpose whatsoever without prior permission in writing from UNODC. Applications for such permission, with a statement of purpose and intent of the reproduction, should be addressed to the Research and Trend Analysis Branch of UNODC. DISCLAIMER The content of this publication does not necessarily reflect the views or policies of UNODC or contributory organizations, nor does it imply any endorsement. Comments on the report are welcome and can be sent to: Division for Policy Analysis and Public Affairs United Nations Office on Drugs and Crime PO Box 500 1400 Vienna Austria Tel: (+43) 1 26060 0 Fax: (+43) 1 26060 5827 E-mail: [email protected] Website: www.unodc.org/wdr2019 PREFACE The findings of this year’s World Drug Report fill in same time clamping down on organized crime and and further complicate the global picture of drug trafficking.
    [Show full text]
  • 0 Cover Part Two\374
    PART TWO DEUXIÈME PARTIE SEGUNDA PARTE ﺍﳉﺰﺀ ﺍﻟﺜﺎﱐ 第二部分 ЧАСТЬ ВТΟΡАЯ - (...), [...] - (-)-3-hidroxi-N- (-)-(2R)-N-méthyl-1- fenacilmorfinán → Levophenacyl-morphan phénylpropan-2-amine → Levometamfetamine (-)-3-hidroxi-N- (-)-(3S,6R)-6- metilmorfinán → Levorphanol (dimethylamino)-4,4- (-)-3-hydroksymorfinan → Norlevorphanol diphenyl-3-heptanol → Betamethadol (-)-3-hydroksy-N- (-)-(3S,6R)-6- fenacylmorfinan → Levophenacyl-morphan (dimethylamino)-4,4- (-)-3-hydroksy-N- diphenyl-3-heptanol metylmorfinan → Levorphanol acetate (ester) → Betacetylmethadol (-)-3-hydroxymorphinan → Norlevorphanol (-)-(5R)-4,5-epoxy-3- (-)-3-hydroxy-N- methoxy-9α-methyl methylmorphinan → Levorphanol → Thebacon morphin-6-en-6-yl acetate (-)-3-hydroxynormorphinan → Norlevorphanol (-)-(5R,6S)-3-benzyloxy-4,5- (-)-3-hydroxy-N- epoxy-9a-methylmorphin- phenacylmorphinan → Levophenacyl-morphan 7-en-6-yl myristate → Myrophine (-)-3-hydroxytropane-2- (-)-(5R,6S)-4,5-epoxy carboxylat → Ecgonine morphin-7-en-3,6-diol → Normorphine (-)-3-idrossi-N- (-)-(5R,6S,14S)-4,5-epoxy- metilmorfinano → Levorphanol 14-hydroxy-3-methoxy- (-)-3-methoxy-N- 9a-methylmorphinan-6- methylmorphinan → Levomethorphan one → Oxycodone (-)-3-metil-2,2-difenil-4- (-)-(R)-4,5-epoxy-3- morfolinbutirilpirrolidina → Levomoramide methoxy-9a-methyl (-)-3-metoksy-N- morphinan-6-one → Hydrocodone metylmorfinan → Levomethorphan (-)-(R)-6-(dimethylamino)- (-)-3-metossi-N-metil- 4,4-diphenyl-3-heptanone → l-methadone morfinano → Levomethorphan (-)-(R)-N,α-dimethyl (-)-3-metoxi-N- phenethylamine → Levometamfetamine
    [Show full text]
  • Levorphanol Use: Past, Present and Future
    Postgraduate Medicine ISSN: 0032-5481 (Print) 1941-9260 (Online) Journal homepage: http://www.tandfonline.com/loi/ipgm20 Levorphanol Use: Past, Present and Future Jeffrey Gudin, Jeffrey Fudin & Srinivas Nalamachu To cite this article: Jeffrey Gudin, Jeffrey Fudin & Srinivas Nalamachu (2015): Levorphanol Use: Past, Present and Future, Postgraduate Medicine, DOI: 10.1080/00325481.2016.1128308 To link to this article: http://dx.doi.org/10.1080/00325481.2016.1128308 Accepted author version posted online: 03 Dec 2015. Submit your article to this journal View related articles View Crossmark data Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=ipgm20 Download by: [Jeffrey Fudin] Date: 03 December 2015, At: 20:32 Publisher: Taylor & Francis Journal: Postgraduate Medicine DOI: 10.1080/00325481.2016.1128308 Levorphanol Use: Past, Present and Future Authors: Jeffrey Gudin1, Jeffrey Fudin2, and Srinivas Nalamachu3 Affiliations: 1Director, Pain Management and Palliative Care, Englewood Hospital and Medical Center, Englewood, NJ, and Clinical Instructor, Anesthesiology, Icahn School of Medicine at Mount Sinai, New York, NY. 2Adjunct Associate Professor, Albany College of Pharmacy and Health Sciences and also Western New England University College of Pharmacy Director, PGY2 Pain Residency and Clinical Pharmacy, Specialist, Pain Management Stratton VA Medical Center, Albany, NY 3President and Medical Director, International Clinical Research Institute, Overland Park, KS, and Adjunct Associate Professor, Temple University School of Medicine, Downloaded by [Jeffrey Fudin] at 20:32 03 December 2015 Philadelphia, PA. Running Title: Levorphanol Use: Past, Present and Future Corresponding Author Srinivas Nalamachu Srinivas R. Nalamachu MD International Clinical Research Institute, Inc.
    [Show full text]
  • Use of Chronic Opioid Therapy in Chronic Noncancer Pain CHRONIC NONCANCER PAINNONCANCER CHRONIC Evidence Review
    CLINICAL GUIDELINE FOR THE USE OF CHRONIC OPIOID THERAPY IN CLINICAL GUIDELINE FOR THE USE OF CHRONIC OPIOID THERAPY IN GUIDELINE FOR THE Use of Chronic Opioid Therapy in Chronic Noncancer Pain CHRONIC NONCANCER PAIN Evidence Review The American Pain Society in Conjunction with The American Academy of Pain Medicine EVIDENCE REVIEW APS-AAPM Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain TABLE OF CONTENTS Page Introduction 1 Purpose of evidence review ...................................................................... 1 Background 1 Previous guidelines ................................................................................... 2 Scope of evidence review 3 Key questions............................................................................................ 3 Populations................................................................................................ 7 Interventions.............................................................................................. 8 Outcomes.................................................................................................. 8 Conflict of interest............................................................................................. 10 Methods 10 Literature search and strategy................................................................... 10 Inclusion and exclusion criteria.................................................................. 11 Data extraction and synthesis ..................................................................
    [Show full text]
  • The International Drug Control Conventions
    ST/CND/1/Add.1 The International Drug Control Conventions Schedules of the Single Convention on Narcotic Drugs of 1961 as amended by the 1972 Protocol, as at 25 September 2013 UNITED NATIONS New York, 2013 ST/CND/1/Add.1 © United Nations, 2013. All rights reserved, worldwide. Schedules of the Single Convention on Narcotic Drugs of 1961 as amended by the 1972 Protocol, as at 25 September 2013 List of drugs included in Schedule I Acetorphine 3-O-Acetyltetrahydro-7α-(1-hydroxy-1-methylbutyl)- 6,14-endo-ethenooripavine Acetyl-alpha-methylfentanyl N-[1-(α-Methylphenethyl)-4-piperidyl]acetanilide Acetylmethadol 3-Acetoxy-6-dimethylamino-4,4-diphenylheptane Alfentanil N-[1-[2-(4-Ethyl-4,5-dihydro-5-oxo-1H-tetrazol-1-yl) ethyl]-4-(methoxymethyl)-4-piperidinyl]-N- phenylpropanamide Allylprodine 3-Allyl-1-methyl-4-phenyl-4-propionoxypiperidine Alphacetylmethadol α-3-Acetoxy-6-dimethylamino-4,4-diphenylheptane Alphameprodine α-3-Ethyl-1-methyl-4-phenyl-4-propionoxypiperidine Alphamethadol α-6-Dimethylamino-4,4-diphenyl-3-heptanol alpha-methylfentanyl N-[1-(α-Methylphenethyl)-4-piperidyl]propionanilide alpha-methylthiofentanyl N-[1-[1-Methyl-2-(2-thienyl)ethyl]-4-piperidyl] propionanilide Alphaprodine α-l,3-Dimethyl-4-phenyl-4-propionoxypiperidine Anileridine 1-p-Aminophenethyl-4-phenylpiperidine-4-carboxylic acid ethyl ester Benzethidine 1-(2-Benzyloxyethyl)-4-phenylpiperidine-4-carboxylic acid ethyl ester Benzylmorphine 3-Benzylmorphine Betacetylmethadol β-3-Acetoxy-6-dimethylamino-4,4-diphenylheptane beta-Hydroxyfentanyl N-[1-(β-Hydroxyphenethyl)-4-piperidyl]
    [Show full text]